Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: bioengineering – Page 120

One of the most remarkable recent advances in biomedical research has been the development of highly targeted gene-editing methods such as CRISPR that can add, remove, or change a gene within a cell with great precision. The method is already being tested or used for the treatment of patients with sickle cell anemia and cancers such as multiple myeloma and liposarcoma, and today, its creators Emmanuelle Charpentier and Jennifer Doudna received the Nobel Prize in chemistry.

While is remarkably precise in finding and altering genes, there is still no way to target treatment to specific locations in the body. The treatments tested so far involve removing or immune system T cells from the body to modify them, and then infusing them back into a patient to repopulate the bloodstream or reconstitute an immune response—an expensive and time-consuming process.

Building on the accomplishments of Charpentier and Doudna, Tufts researchers have for the first time devised a way to directly deliver gene-editing packages efficiently across the and into specific regions of the brain, into immune system cells, or to specific tissues and organs in mouse models. These applications could open up an entirely new line of strategy in the treatment of neurological conditions, as well as cancer, infectious disease, and autoimmune diseases.

Read more | >

Perhaps in the future, gene editing may allow retinal regeneration in humans to reverse age-related vision deterioration.

Damage to the retina is the leading cause of blindness in humans, affecting millions of people around the world. Unfortunately, the retina is one of the few tissues we humans can’t grow back.

Unlike us, other animals such as zebrafish are able to regenerate this tissue that’s so crucial to our power of sight. We share 70 percent of our genes with these tiny little zebrafish, and scientists have just discovered some of the shared genes include the ones that grant zebrafish the ability to grow back their retinas.

“Regeneration seems to be the default status, and the loss of that ability happened at multiple points on the evolutionary tree,” said Johns Hopkins University neuroscientist Seth Blackshaw.

Read more | >

Although it’s clearly NOT the approach taken for ultracold vitrification of patients undergoing life extension cryonization. (ULTRA🥶COLD being the exact opposite of ULTRA-BLOODY-H🥵T, obviously!)

Still, given the vast number of scientific and engineering discoveries and creations born on the backs of unexpected results, accidental discoveries, and outright screw up, it might have very useful data that has practical applications that would never otherwise have even been considered.

Italian scientists found intact brain cells in a man who was killed during the eruption of Mount Vesuvius in 79 AD.

Read more | >

Founder of MakeLoveNotPorn, and internationally famous advertising executive and public speaker, talks of Sex-Tech, a burgeoning trillion dollar industry, on the ideaXme show — #Ideaxme #MoveTheHumanStoryForward #CindyGallop #MakeLoveNotPorn #SexTech #Sexuality #SociallyAcceptableSex #Pornography #Porn #Orgasm #ErectileDysfunction #Biohacking #Viagra #Wellness #Health #Longevity #DisruptAging #Aarp #IfWeRanTheWorld #BartleBogleHegarty #Advertising #PublicRelations #TEDTalk #IraPastor #Bioquark #Regenerage AARP Disrupt Aging.

Read more | >

Synthetic biology startups raised some $3 billion through the first half of 2020, up from $1.9 billion for all of 2019, as the field brings the science of engineering to the art of life.

The big picture: Synthetic biologists are gradually learning how to program the code of life the way that computer experts have learned to program machines. If they can succeed — and if the public accepts their work — synthetic biology stands to fundamentally transform how we live.

What’s happening: SynBioBeta, synthetic biology’s major commercial conference, launched on Tuesday, virtually bringing together thousands of scientists, entrepreneurs, VCs and more to discuss the state of the field.

Read more | >

Two active genetics strategies help address concerns about gene-drive releases into the wild.

In the past decade, researchers have engineered an array of new tools that control the balance of genetic inheritance. Based on CRISPR technology, such gene drives are poised to move from the laboratory into the wild where they are being engineered to suppress devastating diseases such as mosquito-borne malaria, dengue, Zika, chikungunya, yellow fever and West Nile. Gene drives carry the power to immunize mosquitoes against malarial parasites, or act as genetic insecticides that reduce mosquito populations.

Although the newest gene drives have been proven to spread efficiently as designed in laboratory settings, concerns have been raised regarding the safety of releasing such systems into wild populations. Questions have emerged about the predictability and controllability of gene drives and whether, once let loose, they can be recalled in the field if they spread beyond their intended application region.

Read more | >

David Sinclair wants to slow down and ultimately reverse aging. Sinclair sees aging as a disease and he is convinced aging is caused by epigenetic changes, abnormalities that occur when the body’s cells process extra or missing pieces of DNA. This results in the loss of the information that keeps our cells healthy. This information also tells the cells which genes to read. David Sinclair’s book: “Lifespan, why we age and why we don’t have to”, he describes the results of his research, theories and scientific philosophy as well as the potential consequences of the significant progress in genetic technologies.

At present, researchers are only just beginning to understand the biological basis of aging even in relatively simple and short-lived organisms such as yeast. Sinclair however, makes a convincing argument for why the life-extension technologies will eventually offer possibilities of life prolongation using genetic engineering.

He and his team recently developed two artificial intelligence algorithms that predict biological age in mice and when they will die. This will pave the way for similar machine learning models in people.
The loss of epigenetic information is likely the root cause of aging. By analogy, If DNA is the digital information on a compact disc, then aging is due to scratches. What we are searching for, is the polish.

Every time a cell divides, the DNA strands at the ends of your chromosomes replicate in order to copy all the genetic information to each new cell, and this process is not perfect. Over time, however, the ends of your chromosomes can become scrambled.

However, the progress in genetic engineering has proved that these changes can be reversed even at the cellular level, and it is possible to restore the information in our cells, thus improving the functioning of our organs and slowing the aging process.

#Aging #DavidSinclair #Lifespan

Continue reading “Harvard Professor Wants to Slow Down & Reverse Aging: David Sinclair’s Approach For a Longer Life” | >

Wouldn’t it be better to have a creature, something furry and warm that had the ability to produce perfect breast milk? A non-sentient, biological organism that has been engineered to produce milk nutritionally equivalent to mother’s milk? A milk Tribble? That type of technology would be awesome for babies.

Karl Schmieder: Is there a biological technology that you wished you had?

Andrew Hessel: I want the enzymatic DNA synthesizer that will be at least a thousand times better than what we have today. Next-generation sequencing technology massively accelerated our ability to read DNA. An enzymatic DNA synthesizer could be the equivalent accelerator for engineered biology. If you can synthesize DNA faster, then you can conduct more experiments and learn faster. That’s what I’d like to see. More people programming life.

Read more | >

In the past decade, researchers have engineered an array of new tools that control the balance of genetic inheritance. Based on CRISPR technology, such gene drives are poised to move from the laboratory into the wild where they are being engineered to suppress devastating diseases such as mosquito-borne malaria, dengue, Zika, chikungunya, yellow fever and West Nile. Gene drives carry the power to immunize mosquitoes against malarial parasites, or act as genetic insecticides that reduce mosquito populations.

Although the newest gene drives have been proven to spread efficiently as designed in laboratory settings, concerns have been raised regarding the safety of releasing such systems into wild populations. Questions have emerged about the predictability and controllability of gene drives and whether, once let loose, they can be recalled in the field if they spread beyond their intended application region.

Now, scientists at the University of California San Diego and their colleagues have developed two new active genetic systems that address such risks by halting or eliminating gene drives in the wild. On Sept.18, 2020 in the journal Molecular Cell, research led by Xiang-Ru Xu, Emily Bulger and Valentino Gantz in the Division of Biological Sciences offers two new solutions based on elements developed in the common fruit fly.

Read more | >

Myotonic dystrophy type I is the most common type of adult-onset muscular dystrophy. People with the condition inherit repeated DNA segments that lead to the toxic buildup of repetitive RNA, the messenger that carries a gene’s recipe to the cell’s protein-making machinery. As a result, people born with myotonic dystrophy experience progressive muscle wasting and weakness and a wide variety of other debilitating symptoms.

CRISPR-Cas9 is a technique increasingly used in efforts to correct the genetic (DNA) defects that cause a variety of diseases. A few years ago, University of California San Diego School of Medicine researchers redirected the technique to instead modify RNA in a method they call RNA-targeting Cas9 (RCas9).

In a new study, publishing September 14, 2020 in Nature Biomedical Engineering, the team demonstrates that one dose of RCas9 gene therapy can chew up toxic RNA and almost completely reverse symptoms in a mouse model of myotonic dystrophy.

Read more | >